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ABSTRACT 
 
Hepatitis C virus (HCV) causes a significant health problem worldwide due to the 
lack of effective vaccines. It has been recognized that a rapid, vigorous, and broadly 
targeted cell-mediated immune response (Th1-like) is often associated with the 
clearance of HCV infections. DNA vaccines represent a promising means for HCV 
vaccination because they tend to induce a Th1-biased cell-mediated response in the 
host cell. Currently, the delivery of DNA vaccine for HCV in large animals as well as 
in humans is not as effective as in small animals. Nano delivery systems would be a 
promising approach to overcome this problem. Carbon nanotubes (CNTs) have been 
extensively studied for delivering drugs, proteins, peptides, and nucleic acids 
including plasmid DNA to cells and organs with varying degrees of success, but few 
of them have been applied to DNA vaccine for HCV. 
 
This thesis presents a study of using functionalized CNTs (f-CNTs) to improve the 
efficacy of plasmid DNA vaccine delivery for HCV. First, CNTs were functionalized 
via 1,3-dipolar cycloaddition reaction with the appropriate amino acids and aldehydes. 
NMR and TEM results suggested that the CNTs were successfully functionalized and 
became soluble in water. Then plasmid DNAs which encode green fluorescence 
protein reporter gene, luciferase reporter gene, and HCV core protein, respectively, 
were delivered into human hepatoma cells via calcium phosphate precipitation 
method, f-CNT delivery system, and a combination of f-CNT and calcium phosphate 
 ii
method, respectively. The result showed that f-CNTs, in combination with the 
calcium phosphate method, significantly enhanced the gene expression in human 
hepatoma cells. 
 
Consequently, this study concludes that the f-CNT can significantly enhance gene 
expression in liver cells conferred by a plasmid DNA when combined with calcium 
phosphate precipitation method. Even though the mechanisms of this enhancement 
await further investigation, the results of this thesis may have important implications 
in developing DNA vaccines for infectious diseases in general and for hepatitis C in 
particular. 
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Chapter 1  
Introduction  
 
1.1 Background and Motivation 
 
Hepatitis C virus (HCV) is the causative agent of non-A, non-B hepatitis. With 
approximately 170 million infected people in the world, HCV causes a major health 
problem worldwide. This virus often leads to chronic infection that can lead to 
chronic liver diseases, including cirrhosis and hepatocellular carcinoma. 
Unfortunately, there is no effective vaccine available to prevent HCV infections [Lee 
et al., 1998; Geissler et al., 1997; Tokushige et al., 1996; Li et al., 2006]. 
  
For some viral diseases, such as hepatitis C or AIDS, the use of live attenuated virus 
as vaccines is considered to be too risky, because there are chances that the weakened 
virus could revert to the virulent form and cause diseases [Azad et al., 2006]. It has 
been accepted that the clearance of the hepatitis C virus infection is often associated 
with a rapid, robust, and broadly targeted cell-mediated immune response. DNA 
vaccine tends to induce a Th1-biased cell-mediated response in the host, and thus 
becomes a promising approach for generating immunity which can prevent HCV 
infection [Donnelly et al., 1997]. 
 
However, the immune responses induced by DNA vaccines were usually found to be 
too weak to show sufficient protection against new infection, especially in large 
animals and humans. One of the reasons could be that the current delivery system of 
DNA vaccines is not effective in conferring gene expression to a level that is required 
for inducing sustained immunity. 
 
With the rapid development of nanotechnology, it is becoming feasible that a 
nanomaterial-based delivery system might be a promising approach to overcome 
some shortcomings of the conventional delivery system. Nanomaterials, such as 
biodegradable polymers, carbon nanotubes, and carbon 60 fullerenes, have novel 
properties that can improve the efficiency of drug delivery [LaVan et al., 2003]. As a 
novel nanomaterial, carbon nanotubes (CNTs) have attracted considerable attention 
for their potential biomedical and biotechnological applications [Pantarotto et al., 
2003a; Bianco et al., 2005a]. However, pristine CNTs might cause toxicity in 
mammalian cells or organs [Colvin, 2003]. Their biocompatibility has been made 
possible by the chemical functionalization of their surface through treatment by 
peptides, proteins, and other chemicals [Pantarotto et al., 2003b; Karajanagi et al., 
2006; Pastorin et al., 2006]. Functionalized CNTs (f-CNTs) could become 
biocompatible, not immunogenic, and have low toxicity [Bianco et al., 2005b] for 
interacting with biological components including mammalian cells. Functionalized 
CNTs have been tested to deliver drugs, proteins, peptides, and nucleic acids 
including plasmid DNAs to cells, organs and animals. The systems based on the 
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functionalized CNTS have a high potential to enhance the immune responses induced 
by DNA vaccines for infectious diseases, e.g., hepatitis C. Currently, functionalized 
CNTs have been extensively tested for gene delivery with varying degrees of success 
in vitro[Bianco et al., 2005c; Cai et al., 2006]. However, they have not been shown to 
be effective in HCV vaccination. This thesis work was to study the impact of 
functionalized CNTs on gene expression with potential implication in developing 
effective DNA vaccines for infectious diseases such as hepatitis C. 
 
1.2 Hepatitis C Virus 
 
Hepatitis C virus (HCV) is the major etiologic agent of sporadic and 
transfusion-associated non-A, non-B hepatitis worldwide. Up to 3.0% of the world’s 
population has been infected with HCV. With the diagnostic tests of excluding 
HCV-contaminated blood products, the incidence of new HCV infections has 
declined drastically. However, there are still about 170 million people who are 
persistently infected with this virus and have a high risk of developing severe chronic 
liver diseases [Lee et al., 1998; Geissler et al., 1997; Tokushige et al., 1996; Li et al., 
2006]. 
 
HCV is a 33 nm-long positive-strand RNA enveloped virus that belongs to the 
Flaviviridae family and genus Hepacivirus. Figure 1.1 illustrates the organization of 
the virus: it is a microsphere with RNA genome encapsidated by the viral core particle 
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which is encoded by the HCV Core gene. The viral surface is surrounded by a lipid 
envelope containing glycoproteins E1 and E2 that are encoded by the HCV E1 and E2 
genes, respectively. 
 
 
Figure 1.1 The model structure of HCV virion. 
 
In the structure of HCV genome (Figure 1.2), a 5’-untranslated region is followed by 
an open reading frame which is further followed by another untranslated region at the 
3’ end. The open reading frame encodes for a single polyprotein which, upon protease 
digestions, gives rise to several proteins in the order from 5’ to 3’: C, E1, E2, p7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B. The C, E1, and E2 proteins are structural and 
the NS2, NS3, NS4A, NS4B, NS5A and NS5B proteins are nonstructural 
[Lindenbach et al., 2004]. 
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 Figure 1.2 HCV Genome. 
 
HCV replicates in the liver, and is detectable in sera during acute and chronic 
infection. Although the life cycle (Figure 1.3) of HCV is poorly understood, a 
possible sequence of biological events has been postulated to explain how the virus 
enters a liver cell, makes copies of itself and then exits to infect other cells.  
 
Figure 1.3 Hepatitis C virus life cycle. This figure is cited from: 
http://www.tibotec.com/content/backgrounders/www.tibotec.com/hcv_lifecycle.html. 
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 HCV particles, or “virions”, bind with a receptor on the surface of the cell membrane 
and is endocytosed. Then, the virions somehow fuse themselves with the endocytotic 
vesicle membrane to deliver a complex of RNA and associated proteins into the 
cytoplasm of the liver cell. Viral RNAs are translated by ribosomes into a polyprotein, 
which is then cleaved into structural and non-structural proteins. The same RNAs are 
also copied into complementary RNAs that serve as templates for making RNA 
copies. The numerous copies of RNA made through this process then join with the 
viral proteins to form virions. The virions are secreted from the liver cell via the cell’s 
secretory pathway, releasing the new virions to infect a large number of new liver 
cells.  
 
1.3 Immune responses to antigens 
 
Our immune system plays the most important role in vaccination. The immune system 
works in response to “foreign” molecules, such as bacteria or viruses. Table 1.1 
describes common components that are involved in immune responses [Azad et al., 
2006] and Figure 1.4 briefly shows the major processes of two general types of 
immunity: humoral immunity and cell-mediated immunity. 
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Table 1.1 Components of the Immune system 
Component Description 
Ag Antigen; usually proteins or polysaccharides which are parts of bacteria, viruses, 
or other microorganisms; can cause the generation of antibodies and an immune 
response. 
DC Dendritic cells; immune cells; form part of the mammalian immune system; 
function as antigen-presenting cells. 
B cells B lymphocytes; white blood cells produced in the bone marrow. 
T cells T lymphocytes; white blood cells derived from the thymus gland. 
MHC I Major histocompatibility complex class I molecules; found on almost every 
nucleated cell of the body.  
MHC II Major histocompatibility complex class II molecules; found only on a few 
specialized types of cells, including macrophages and B cells. 
Th cells Helper T cells; also known as CD4+ T cells, a sub-group of T cells. 
CTL Cytotoxic T Lymphocytes; also knows as CD8+ T cells, a sub-group of T cells. 
Ab Antibody, also known as immunoglobulin; identify and neutralize antigen. 
 
 
 7
 Figure 1.4 Humoral immunity and cell-mediate immunity. 
 
An antigen may induce both humoral immunity and cell-mediated immunity [Davis et 
al., 1999]. Humoral immunity usually involves B cells. When B cells recognize an 
antigen via their surface receptors, the antigen will be displayed on the B cell surface 
bound to MHC II molecules. MHC II is then recognized by the receptors on the Th 
cell surface (process ①), Th cells release stimulatory molecules that in turn to activate 
B cells (process ②). In process ③, part of activated B cells become plasma cells, 
considered as an “antibody factory” which can produce a large amount of antibodies 
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and secrete them into body fluids (process ④) to destroy the antigen. Other parts of B 
cells that have not involved in process ③ and process ④ become memory cells that 
are able to live for a long time and can respond quickly following a second exposure 
to the same antigen.  
 
T cells are the effectors for cell-mediated immunity. After an antigen is recognized by 
receptors on DC, the antigen is engulfed and then presented on the DC surface by 
MHC I molecules that are subsequently recognized by Th cells via process ⑤. Th 
cells in turn stimulate T cells (process ⑥) to produce CTLs (process ⑦). Once CTLs 
become activated, they are capable of destroying infected cells, while bypassing 
normal cells (process ⑧). 
 
The real immune system and immune responses are much more complicated than the 
aforementioned processes. However, it is certain that humoral immunity and 
cell-mediate immunity cannot be separated, and they work collaboratively to produce 
our immune responses. 
 
1.4 DNA vaccine 
 
The DNA vaccines (Fig. 1.5) [Liu, 2003], also known as genetic vaccines or nucleic 
acid vaccines, are simple rings of DNA, that are bacterially derived plasmids (Fig. 
1.6), containing a gene encoding the desired antigen, and a promoter/terminator to 
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enable gene expression in mammalian cells. A DNA vaccine construction process 
usually involves (i) isolating one or more genes from a disease-causing agent (e.g., 
HCV) with known antigenic properties and (ii) cloning these genes into plasmids. 
 
 
Figure 1.5 A schematic representation of a DNA vaccine. 
 
 
Figure 1.6 A schematic representation of plasmid DNA. This figure is cited from: 
http://upload.wikimedia.org/wikipedia/commons/d/da/Making_of_a_DNA_vaccine.jpg 
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DNA vaccination is a promising approach for generating all types of desired immune 
responses: cytolytic T lymphocytes (CTL) responses, T helper cells responses, and 
antibody responses, whilst being a technology that has the potential for global usage 
in terms of ease of manufacturing, broad population administration and safety [Liu, 
2003]. 
 
Immunizing the host with a DNA vaccine encoding a viral antigen rather than an 
antigenic protein of the virus (a subunit vaccine) helps to stimulate the generation of 
cell-mediated immunity (Fig. 1.7). 
 
 
Figure 1.7 How DNA vaccines work. This figure is cited from: 
http://www.medscape.com/content/1998/00/40/87/408733/art-mrc4593.fig2.jpg. 
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 DNA vaccines favor a cell-mediated immune response. Plasmid DNA vector vaccines 
carry the genetic information encoding an antigen to a host cell, allowing the antigen 
to be produced inside the host cell, leading to a cell-mediated immune response (in 
particular via the MHC I pathway). The plasmid DNA vaccine carries the genetic 
code for an antigen. The plasmid vector is taken up into cells and transcribed to RNA 
in the nucleus (1). The single stranded mRNA (2) is translated into proteins in the 
cytoplasm. The DNA vaccine-derived protein antigen (3) is then degraded by 
proteosomes into intracellular peptides (4). The vaccine-derived peptide binds MHC I 
molecules (5). Peptide antigen/MHC I molecules are presented on the cell surface (6), 
binding cytotoxic CD8+ lymphocytes, and inducing a cell-mediated immune response. 
Because DNA vaccines generate cell-mediated immunity, they may be effective 
against viruses where subunit vaccines have failed. 
 
DNA vaccines may have significant advantages over subunit vaccines. They can 
express antigenic epitopes which more closely resemble native viral epitopes and 
could therefore be more effective. With live attenuated vaccines and killed vaccines 
the manufacturing process can alter the secondary and tertiary structure of the proteins 
and therefore the antigenicity of the vaccine; with naked DNA vaccines, the host cell 
is manufacturing the viral epitope. DNA vaccines would be safer than live virus 
vaccines, especially in immunocompromised patients, such as those infected with 
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HIV. DNA vaccines may be constructed to include genes against several different 
pathogens, thus decreasing the number of vaccinations necessary to fully immunize 
children. Construction of DNA vaccines is relatively simple. Finally, DNA vaccines 
may hold some promise in treating those already infected with chronic viral infections 
as therapeutics. 
 
1.5 Carbon Nanotubes 
 
Since carbon nanotubes (CNTs) were first published by Japanese scientist Iijima in 
1991 [Iijima, 1991], CNTs became a subject of intensive research interest [Bianco et 
al., 2005a; 2005b]. Significant attention is being paid to applications of CNTs in 
mechanics, nanotechnology and engineering, electronics, optics, biomedicines and 
other fields of materials science due to its unique properties. There are two major 
types of CNTs, single-wall carbon nanotubes and multi-wall carbon nanotubes. 
 
A single-wall carbon nanotube (SWNT) can be viewed as a rolled-up rectangular strip 
of hexagonal graphite monolayers (Figure 1.8), while a multi-wall carbon nanotube 
(MWNT) is rolled-up with many layers of such strips (Figure 1.9) 
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 Figure 1.8 Single-walled carbon nanotube. This figure is cited from: 
http://www.ewels.info/img/science/nano.html. 
 
 
Figure 1.9 Multi-walled carbon nanotube. This figure is cited from: 
http://students.chem.tue.nl/ifp03/. 
 
CNTs are usually only a few nanometers in diameter but could be up to micro-scale in 
length. This structure can have a length-to-diameter ratio greater than 1,000,000 and 
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gives CNTs a property different from most other nanomaterials which are generally 
spherical in their shape. CNTs are potentially a good carrier for drug delivery – 
especially protein drug delivery. 
 
However, pristine CNTs are completely insoluble in almost all solvents [Bianco et al., 
2005c] and could cause some health concern because of their potential toxicity 
[Colvin, 2003]. Fortunately, the development of efficient methodologies for the 
chemical modification of CNTs, also known as “functionalization”, has stimulated the 
perparation of soluble CNTs that can be utilized in drug delivery and vaccine delivery. 
A review of CNT functionalization methodologies will be given in Chapter 2. 
 
1.6 Research Objectives 
 
Most experiments have demonstrated that a DNA vaccine for HCV can elicit immune 
responses in small animals; however, its immune responses in large animals and 
humans are usually too weak to protect against new infection. One possible reason is 
that the level of gene expression conferred by DNA vaccines is not high enough to 
induce sustained immune responses. Functionalized CNTs may be able to enhance the 
efficacy of DNA vaccine by enhancing gene expression. This study aims to determine 
whether an f-CNTs-based delivery system increases gene expression by a plasmid 
DNA.  
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In particular, this study has the following specific research objectives:  
(1) Functionalization of pristine CNTs; 
(2) Design and construction of an f-CNT delivery system that can carry plasmid 
DNAs; and 
(3) Evaluation of whether the f-CNT system can enhance gene expression after 
transfecting plasmid DNAs in vitro.  
 16
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Chapter 2 
Background and Related Work 
 
2.1 DNA Vaccines for Hepatitis C Virus 
 
Although approximately, 3% of the world’s population is infected with hepatitis C 
virus, there is no effective vaccine available [Li et al., 2006]. There are many 
obstacles to the development of a vaccine against HCV [Lechmann et al., 2000]. The 
fact that HCV can mutate rapidly, allowing it to adapt to new environments is one of 
them. Most difficult, however, is the finding that HCV infection does not seem to 
induce a sterile immunity; in other words, reinfection of different or even identical 
strains can occur after recovery from a previous infection [Bukh et al., 2001]. This 
finding indicates that inducing high-titer, long-lasting, and cross-reactive antibodies 
and a cellular immune response that includes both helper and cytotoxic T 
lymphocytes may be necessary for an effective vaccine. Promising vaccine candidates 
such as DNA vaccine have been explored and shown to have many advantages. 
 
A DNA-based vaccine usually consists of a plasmid DNA that carries sequences 
encoding an antigen of interest under the control of a strong promoter. DNA vaccines 
could be designed to bias the type of T helper cell towards a Th1 or Th2 response 
[Feltquate et al., 1997]. DNA immunization is able to raise T helper cell responses, 
CTL responses, and antibody responses. Many studies have been conducted on the 
development of DNA-based vaccines against HCV. 
 
HCV core protein represents a valuable target in the development of vaccines, 
because it is the most conserved viral antigen [Brinster et al., 2001]. Lagging et al. 
[1995] investigated immune responses to plasmid DNA encoding the HCV core 
protein. The result from intramuscular inoculation of mice indicated that the DNA 
vaccine generated HCV core-specific antibody responses, lymphoproliferative 
responses, and CTL activity. A team from the U.S. [Tokushige et al., 1996] generated 
a strong CD8+ T lymphocyte activity both in vivo and in vitro by utilizing DNA 
vaccine pHCV2-2 (containing the entire HCV core region) and pHCV4-2 (containing 
both the 5’ noncoding region and the core region). Similarly, in another study [Arichi 
et al., 2000], HLA-A2.1-transgenic mice were inoculated with a plasmid DNA 
vaccine encoding the HCV core antigen. The immunization elicited CTLs and 
persisted at least 14 months, and this process has shown to be mediated by CD8+ cells. 
Further, when challenged, the DNA immunized mice showed a substantial reduction 
in vaccinia virus titer compared with the mock-immunized controls. 
 
Because of the high degree of genetic heterogeneity exhibited by HCV envelope 
glycoproteins, it is not at first obvious to include them in a vaccine preparation; in 
addition, the great capacity of the E2 hypervariable region 1 (HVR1) to mutate 
appears to be mainly responsible for the appearance of immune escape mutants 
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[Shimizu et al., 1996]. Forns et al. [2000] used a DNA vaccine encoding HCV 
surface-expressed envelope 2 (E2) glycoproteins to inoculate chimpanzees. One of the 
chimpanzees developed antibodies to E2 and HVR1 after the second and third 
immunization, respectively. A strong CTL response was detected after the HCV 
challenge in one chimpanzee, and an E2-specific CD4+ response was both detected 
before and after challenge in two other chimpanzees. Jin et al. [2002] inoculated mice 
with a plasmid DNA vaccine expressing five fragments of HCV E2 fused to the 
hepatitis B virus surface antigen HBsAg (HBV S). After one primary and one 
boosting immunizations, antibodies against both HBV S and HCV E2 were detected 
in mouse sera and a high-level expression of INF-γ was detected in the cultured 
splenic cells. The results indicated that these fusion constructs could efficiently elicit 
humoral and Th1 dominant cellular immune responses against both HBV S and HCV 
E2 antigens in DNA-immunized mice. In another study [Lee et al., 1998], antibody 
responses against HCV envelope proteins E1 and E2 were induced in the 
immunization of DNA vaccine encoding these proteins in rats. O’Hagan et al. [2004] 
also demonstrated that vaccination of mice with plasmids encoding HCV E1 and E2 
antigens induced humoral and cellular immune responses. 
 
HCV nonstructural (NS) proteins are also interesting vaccine candidates because of 
their crucial functions in the viral life cycle and, consequently, the fact that a number 
of NS-encoded domains are particularly well conserved among the various existing 
genotypes and subtypes [Higashi et al., 1993; Kato et al., 1994]. Brinster et al. [2001] 
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evaluated the immune responses generated by plasmid DNA vaccines, expressing 
HCV NS3 protein both in vitro and in vivo. The plasmids were shown to express a 
protein of expected size and can result in the induction of a stable specific 
CD8+-mediated response. Two other studies [Encke et al., 1998; Cho et al., 1999] on 
DNA immunization utilized plasmids encoding NS3, NS4, and NS5 proteins 
separately or collectively demonstrated that these DNA vaccines successfully induced 
HCV-specific antibodies against those three nonstructural proteins in both mice and 
rats. Both studies have shown that the immunization induces the lymphoproliferative 
responses. 
 
These studies have demonstrated the potency of DNA-based vaccines to induce both 
humoral and cellular immune responses against various HCV proteins. However, the 
responses induced by naked plasmid DNAs are usually very weak. Therefore, the 
delivery of DNA vaccines becomes a crucial step that should be studied in more detail. 
Factors such as the routes and methods of delivery and the delivery systems should be 
studied for a more effective DNA vaccine for HCV. 
 
2.2 DNA Vaccine Delivery System 
 
DNA vaccines are stable, heat-resistant, economical and easily constructed by 
molecular cloning techniques, making them suitable for worldwide application [Davis 
et al., 1999]. However, the immunization efficiency of the plasmid DNA vaccine is 
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usually low in vivo due to the fast degradation of the plasmid DNA during the course 
of delivery [Hurk, 2006]. A proper delivery system becomes critical to the 
development of an effective DNA vaccine. 
 
2.2.1 Routes of administration for DNA vaccine delivery 
 
DNA vaccines have been introduced into animal tissues by a number of different 
methods. The following are a few of the routes of administration for plasmid DNA 
vaccines [Fynan et al., 1995]: 
? IV: Intravenous – within or administered into a vein, 
? IM: Intramuscular –within a muscle, 
? ID: Intradermal –within or between the layers of the skin, 
? IP: Intraperitoneal – within the peritoneal cavity (body cavity), 
? SC: Subcutaneous – within the layer of tissue directly underlying the skin, 
? IN: Intranasal –within the nose, 
? Oral – within the mouth, and 
? Topical – on a body surface. 
 
The most extensively used route for DNA vaccine delivery is the parenteral route, 
including IM, ID, IV, and SC. However, these routes may bring complications with 
delivery systems, because they are all needle-based systems [Azad et al., 2006]. Based 
on the principle that “the delivery methods should be as non-invasive as possible” 
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[Hurk, 2006], topical administration to the skin [Cui et al., 2006], nasal delivery 
[Fynan et al., 1993], and oral administration [Chen et al., 2007] have shown their 
potential by reducing the level of invasiveness while maintaining the efficiency of the 
delivery. 
 
2.2.2 DNA vaccine delivery systems 
 
The barriers for developing an effective DNA vaccine may be circumvented by 
improved delivery systems which are constructed using chemical, mechanical, and 
physical effects or means. Table 2.1 summarizes the delivery systems of DNA 
vaccines and materials of these systems. 
 
Table 2.1 DNA Vaccine Delivery systems and Materials of the Systems 
Delivery System Materials  Routes References 
Chemical 
Liposomes Cationic lipid, 
etc. 
Topical, 
IP, IM, 
ID, SC 
Choi et al., 2006; Lu et al., 2007 
Microparticles Cationic 
polymer, etc. 
ID, oral, 
IM, IP, SC
Kasturi et al., 2006; He et al., 2005; 
Singh et al., 2006; O’Hagan et al., 
2004; Jilek et al., 2005 
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Nanomaterials Biodegradable 
Polymer, 
f-CNTs, Silica, 
CpG ODN, etc. 
Oral, SC, 
ID, IM, 
Topical, 
nasal； IP
Chen et al., 2007; Chong et al., 2005; 
Cohen et al., 2000; Cui et al., 2002, 
2003; Mumper et al., 2003; Vila et al., 
2002; Panyam et al., 2003 Geissler et 
al., 1997; Ouyang et al., 2002; Lee et 
al., 1998; Cui et al., 2003a; Sasaki et 
al., 2003; Li et al., 2006, Hu et al., 
2007, Jeon et al., 2007; Perez et al., 
2001; Pan et al., 2007; Bianco et al., 
2004, 2005; Rojas-Chapana et al., 
2005; Gao et al., 2006; Singh et al., 
2005; Pantarotto et al., 2004 
Mechanical 
Gene gun High-velocity 
bombardment 
ID, oral, 
IM 
Chuang et al., 2005; Chen et al., 1999; 
Wang et al., 2003; Sasaki et al.,2003 
Jet injection High-pressure 
delivery of 
liquid 
ID, SC, 
Topical 
Cui et al., 2003b; Mumper et al., 2003
Physical 
Electroporation Short controlled 
electric pulses 
IM, ID Wideca et al., 2000; Zucchelli et al., 
2000 
Magnetofection Paramagnetic 
particles and 
magnetic field 
IV Mykhaylyk et al., 2007; Dobson, 2006
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 Several materials, including genetic, biological and chemical, are being developed as 
delivery systems for DNA vaccine. Liposomes are synthesized from cholesterol or 
non-toxic lipids. They are considered to be attractive drug delivery carriers. They can 
circulate in the blood stream for a long time without causing health concerns [Yih et 
al., 2006]. Microparticles are small particles ranging from 1 to 100 micrometers in 
size with different shapes. They could be flexible, biodegradable, and biocompatible. 
In a microparticle-based drug delivery system, a broad range of polymers are used to 
encapsulate plasmid DNA. Encapsulating DNA vaccine in polymers makes 
non-invasive delivery, such as oral or nasal delivery, much more promising because 
the entrapped plasmid DNA is protected against degradation in the gut during the 
course of delivery [Azad et al., 2006]. Nanomaterials offer a number of distinct 
advantages over microparticles due to their nano size. They are able to penetrate 
through the submucosal layers while the microparticles are mainly localized in the 
epithelial lining. Nanoparticles have in general a relatively higher intracellular uptake 
compared to microparticles and this property with the nanoparticles shows its more 
promise as a plasmid DNA delivery system [Panyam et al., 2003]. 
 
The most common method for the delivery of a vaccine is injection with syringes and 
needles through intramuscular, intravenous, or intradermal routes. The needle-based 
delivery system could be a painful procedure for animals or humans, especially 
children. Because needle injection is one of the main routes for infection of some viral 
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virus, such as HCV or HIV, needle-based delivery system could create certain 
concerns if they were previously used. Needle-free, less invasive delivery methods for 
plasmid DNA such as jet injection and delivery by gene gun show their advantage 
over needle-based delivery systems [Hurk, 2006]. Electroporation is one of the most 
efficient methods using a high-voltage electrical current to facilitate DNA transfer 
[Patil et al., 2005]. Unfortunately, this technique results in high cell mortality and is 
extremely difficult to apply in vivo and in clinical trails [Luo et al., 2000]. In the 
magnetofection delivery system, DNA vaccine can be attached to magnetic 
nanoparticles and then focused to the target cells, tissues, or organs via high-field 
magnets. This technique increases the speed and level of transfection but meets major 
obstacles such as toxicity issue, difficulties in targeting sites in large animals and 
humans and the complexity in the clinic settings [Dobson et al., 2006]. 
 
2.3 Functionalization of Carbon Nanotubes 
 
Carbon nanotubes (CNTs) are considered to be a promising material for several 
applications, ranging from the mechanical field to biological field. However, the use 
of CNTs as drug delivery system is limited because the pristine ones are completely 
insoluble in all solvents and their toxicity could generate some health concerns 
[Colvin, 2003]. Their compatibility with aqueous environments has been made 
possible by chemical functionalization of their surface. Functionalized CNTs have 
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been explored for their potential as delivery vehicles of biologically active molecules, 
including vaccines [Singh, 2005]. 
 
The approaches of functionalization of CNTs can be classified into covalent and 
noncovalent functionalization [Bianco et al., 2005c]. Covalent functionalization 
(Table 2.2) is based on the covalent linkage of functional groups onto a nanotube’s 
sidewalls or end parts, where the linkage is usually associated with a change of the 
property binding between carbon atoms [Campidelli et al., 2006]. Non-covalent 
functionalization (Table 2.2) is mainly based on supramolecular complexation 
because of various adsorption forces, such as van der Waals’ and π-stacking 
interactions [Hirsch, 2002]. 
 
Table 2.2 Covalent and Noncovalent Functionalization of CNT 
Covalent 
functionalization 
References Noncovalent 
functionalization 
References 
1,3-Dipolar 
cycloaddition 
Tagmatarchis et al., 2004; 
Bianco et al., 2004, 2005; 
Pantarotto et al., 2003, 2004; 
Campidelli et al., 2006; Singh 
et al., 2005; Georgakilas et al., 
2001, 2002; Pastorin et al., 
2006 
Peptides Witus et al., 2007; 
Wang et al., 2003
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Oxidative 
treatment 
Cai et al., 2007; 
Rojas-Chapana et al., 2005; 
Gao et al., 2006; Pan et al., 
2007; Campidelli et al., 2006; 
Hamon et al., 1999; Sun et al., 
2002; Yu et al., 2008 
Proteins Karajanagi et al., 
2006; Shim et al., 
2002 
Ammonium Gao et al., 2006; Pastorin et 
al., 2006; Georgakilas et al., 
2001, 2002; Hamon et al., 
1999; Singh et al., 2005 
Electrografting Petrov et al., 2004
Solvent-free Dyke et al., 2003 Pyrene Campidelli et al., 
2006; Chen et al., 
2001 
Reduction of 
diazonium salts 
Bahr et al., 2001 Poly (acrylic 
acid) 
Liu et al., 2006 
 
Functionalized CNTs can be applied to not only the drug delivery system but also to 
other fields such as optical performance in electrical, emission displays, 
supercapacitors, molecular computers, and ultrahigh-strength materials applications. 
In these latter applications, the CNTs are required to be separated into individual 
tubes or bundles of only a few tubes [Qin et al., 2004], while the high molecular 
weights and strong intertube forces keep the pristine CNTs together in large bundles 
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[Tagmatarchis et al., 2004]. Covalent functionalization of CNTs using addition 
reaction has been considered to be very promising for nanotube modification and 
derivation. One of the most common functionalization techniques is the oxidative 
treatment of nanotubes by liquid or gas phase oxidation, such as the treatment with 
strong acid to introduce the carboxylic group and other groups such as hydroxyl, 
carbonyl, and ester group into the sidewalls of CNTs [Hirsch et al., 2005]. On the 
other hand, the organic functionalization of CNTs is considered to be a powerful 
method to improve the solubility and processibility of CNTs [Tagmatarchis et al., 
2004]. The 1,3-Dipolar cycloaddition of azomethine ylides was originally developed 
for modification of C60 [Maggini et al., 1993; Prato et al., 1998] and then has been 
successfully adapted to functionalizing CNTs [Singh et al., 2005; Pantarooto et al., 
2004; Capidelli et al., 2006; Georgakilas et al., 2002a]. In this treatment, CNTs 
undergo the addition reaction when heated in dimethylformamide (DMF) in the 
presence of a N-substituted amino acid and an aldehyde [Georgakilas et al., 2002b], 
and a large number of pyrrolidine rings are fused to the carbon-carbon bonds of CNTs. 
This could allow for a wide number of other functionalities to be immobilized onto 
the CNTs surface [Banerjee et al., 2005]. Biological moieties can also be introduced 
onto nanotube surfaces using this chemistry. The favorable antigenicity and 
immunogenicity of these nanotube-based conjugates make them very promising in 
vaccine delivery and gene therapy. 
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2.4 Summary 
 
The f-CNTs-based delivery system for plasmid DNA is potentially promising for a 
further improvement of immune responses induced by DNA vaccines against HCV. 
However, understanding of the effect of f-CNTs in the delivery process is not quite 
clear; as such it is necessary to study this system. Although it seems to be promising 
to coat functional group “ammoniums” on the pyrrolidine rings to CNTs, the testing 
result was not very good, suggesting research on new functional groups. 
 
Just similar to any artificial system, design and construction are two major parts for 
the f-CNTs-based delivery system for DNA vaccines of HCV. Here, design refers to 
the selection of CNTs, especially (i) single-wall or multi-wall, (ii) quantity, and (iii) 
purity, and (iv) selection of functionalization of CNTs (especially the type, condition 
of reactions and quantity of chemicals). Construction refers to the actual building of a 
delivery system. Furthermore, testing and evaluation of the delivery system also need 
a careful design with a special reference to the transfection procedure. 
 
This thesis, as also outlined in Chapter 1, will describe a study on the design and 
construction of the f-CNTs-based system for delivering a plasmid DNA encoding 
HCV protein.
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Chapter 3 
Materials and Methods 
 
3.1 Functionalization of CNTs 
 
Functionalization of CNTs in the context of this research is to coat chemicals on the 
surface of CNTs stably. CNTs with few defects would be in favor of such a coating 
process. For this reason, in this research, single-wall CNTs were chosen. Some other 
decisions on what chemicals are chosen and what reactions are chosen were described 
in the following subsections. 
 
3.1.1 General methods and materials 
 
1,3-dipolar cycloaddition reactions are fundamental processes in organic chemistry 
[Pandey et al., 2006]. This reaction has been successfully applied to the organic 
modification of fullerene C60 [Maggini et al., 1993; Prato, 1998]. CNTs could be 
functionalized by this reaction [Georgakilas et al., 2002a]. In particular, the 
1,3-dipolar cycloaddition reaction of azomethine ylides, the reactive intermediates 
that could efficiently attack the vast π-π bonds of the CNTs, is a powerful method to 
produce a large number of pyrrolidines rings fusing to the carbon-carbon bonds 
[Tagmatarchis et al., 2004; Pandey et al., 2006]. Pyrrolidines rings are an important 
building block in the syntheses of many natural products and pharmaceuticals 
[Pandey et al., 2006]. After being functionalized by this type of chemistry, f-CNTs 
could be further modified. 
 
Single-Wall Carbon Nanotubes (SWNTs) used in this work were obtained from 
Carbon Nanotechnologies Inc. (Purified HiPCO Single-Wall Carbon Nanotubes). The 
detailed specification of the SWNTs was provided by Carbon Nanotechnologies Inc. 
Prior to the use of the SWNTs, they were also characterized on Raman spectroscopy 
at Saskatchewan Structural and Science Centre. The result is in consistence with that 
provided by Carbon Nanotechnologies Inc. Triethylene glycol monomethyl ether, 
2-nitrobenzenesulfonyl chloride, and paraformaldehyde were purchased from 
Sigma-Aldrich. Other reagents and solvents used for functionalization of CNTs were 
kindly provided by Dr. Palmer (Department of Chemistry, University of 
Saskatchewan). All these reagents and solvents were purchased reagent grade from 
Sigma-Aldrich and used without further purification. 
 
3.1.2 Synthesis of the N-substituted amino acid 
 
To functionalize CNTs, appropriate amino acids and aldehydes should be applied in 
the 1,3-dipolar cycloaddition reaction. The functional groups present in the starting 
materials are critical elements to render CNTs soluble. This explains the reason for 
choosing the amino acid characterized by the presence of hydrophilic chains – i.e. 
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poly (ethylene glycol) (PEG) chains. PEG is non-toxic, non-immunogenic and highly 
flexible. It can be used in surfaces treatment without interfering cellular functions, 
bioconjugations, or target immunogenicities [Manta et al., 2003; Wood et al., 2005]. 
Using CNTs as a drug delivery system could be achieved by the f-CNTs that are 
functionalized with the N-substituted amino acids characterized by PEG and 
aldehydes via the 1,3-dipolar cycloaddition reaction. 
 
To synthesize this particular N-substituted amino acid, we proposed a method based 
on the methods proposed by Brough [2006] and Sakaguchi [2007]. The general 
motivation of the proposed method was that we failed to functionalize the SWNTs 
based on Brough’s method. 
 
3.1.2.1 Synthesis of N-substituted amino acid with Brough’s method 
 
Compound A 
 
O
O
NH2HCl
NsCl, DIEA
CH2Cl2, 16h, rt
O
O H
N
Ns
A  
 
To a solution of glycine benzyl ester hydrochloride (0.8475 g, 4.2 mmol) and N, 
N-Diisopropylethylamine (DIEA, 1.688 mL, 10.7 mmol) in distilled CH2Cl2 (35 mL), 
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a solution of 2-nitrobenzenesulfonul chloride (NsCl, 1.188 g, 5.3 mmol, 10 mL of 
distilled CH2Cl2) was added dropwise over a period of 1 hour. The solution was 
stirred for 16 hours at room temperature and the reaction mixture was concentrated 
under reduced pressure. The crude mixture was washed with ethyl acetate (50 mL). 
The organic phase was washed with saturated NaHCO3 (2X10 mL) and H2O (2X20 
mL), then dried over Na2SO4, filtered and evaporated to give Compound A as a 
yellow oil. 
 
Compound B 
 
O
O H
N
Ns
DEAD, Ph3P
CH2Cl2, rt, 2h
O
O
N
Ns
O 3
A B  
 
To a solution of triethylene glycol monomethyl ether (0.808 g, 4.92 mmol), 
Compound A (0.575 g, 1.64 mmol) and triphenylphosphine (Ph3P, 0.627g, 2.39mmol) 
in distilled CH2Cl2 (10 mL) were added dropwise into a solution of diethyl 
azodicarboxylate (DEAD, 40%wt, 1.04 g, 2.39 mmol, 5 mL distilled CH2Cl2) over a 
period of 30 minutes. The solution was stirred for a further 2 hours at room 
temperature, and then the reaction mixture was concentrated under reduced pressure. 
The organic phase was extracted with 50 mL of 1M KOH and the aqueous phase was 
re-extracted with ethyl acetate (50 mL), and then the two organic phases were 
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evaporated. The crude mixture was purified using flash chromatography on SiO2 (5% 
CH2Cl2/acetore) giving Compound B as a yellow oil. 
 
Compound C 
 
O
O
N
Ns
O 3
B
HS
OH , LiOH
DMF, 1h, rt
C
LiO
O H
N
O 3
 
 
A solution of Compound B (0.606 g, 1.43 mmol), 2-mercaptoethanol (201.3 μL, 2.9 
mmol) and LiOH (122 mg, 2.9 mmol) in dimethylformamide (DMF, 20 mL) was 
stirred at room temperature for 2 hours. The reaction mixture was concentrated under 
reduced pressure and the crude mixture was extracted with CH2Cl2 (2X20 mL) and 
H2O (20 mL). The aqueous phase was lyophylisated to give the target Compound C 
as a yellow solid. 
 
Our experience of using Brough’s method concludes: (1) the starting material in 
Brough’s method was very difficult in a separation process, and (2) the process from 
Compound B to Compound C involved considerable noises, examined with NMR 
spectrum. For (1), we chose a different starting material (see discussions in the next 
section). For (2), we adopted a method proposed by Sakaguchi et al. [2007], which 
was not used for functionalization of CNTs but general-purpose synthesis of 
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chemicals. In particular, we replaced the process in Brough’s method from 
Compound B to Compound C by two processes which were learned from Sakaguchi 
et al. [2007]. Our new method is presented in the next section. 
 
3.1.2.2 Synthesis of N-substituted amino acid  
 
Compound 1 
 
MeO
O
NH2HCl
NsCl, Et3N
CH2Cl2
0 oC to rt, 12h
MeO
O H
N
Ns
1  
 
To a suspension of Glycine methyl ester hydrochloride (2.45 g, 19.5 mmol) and water 
(1.5 ml) in CH2Cl2 (30 ml), triethylamine (Et3N, 5.5 ml, 39.5 mmol) and 
2-nitrobenzenesulfonyl chloride (NsCl, 4.83 g, 21.8 mmol) were added at 0oC. The 
reaction mixture was gradually warmed up to room temperature. After stirring for 12 
hours, the mixture was concentrated under reduced pressure. After addition of water, 
the mixture was extracted with ethyl acetate three times. The combined organic 
extracts were washed with water and saturated NaHCO3, dried over Na2SO4, filtered, 
and evaporated under reduced pressure. The residue was recrystallized from a mixture 
of ethyl acetate and toluene giving the desired Compound 1 (3.6 g, 67.3%) as a 
colorless solid. 
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1H NMR: δ 8.11-8.09 (m, 1H), 7.96-7.94 (m, 1H), 7.76-7.74 (m, 2H), 6.05 (s, 1H), 
4.03-4.02 (d, 2H), 3.61 (s, 3H). 
 
Compound 2 
 
MeO
O H
N
Ns
DEAD, Ph3P
Toluene
70 oC, 20min
MeO
O
N
Ns
O 3
1 2  
 
A toluene (25 ml) solution of triethylene glycol monomethyl ether (0.821 g, 5 mmol), 
Compound 1 (1.37 g, 5 mmol), and triphenylphosphine (Ph3P, 1.31 g) were warmed 
to 70oC. After DEAD (40%wt, 2.28 ml, 5 mmol) in 5-ml toluene solution was added 
to the mixture above via syringe slowly, the mixture was stirred for 20 minutes at 
70oC. After the mixture was cooled down to room temperature, the reaction mixture 
was concentrated under reduced pressure. The organic phase was extracted with KOH 
(5M, 30 ml) and the aqueous phase was re-extracted with ethyl acetate (50 ml), and 
then the two organic phases were evaporated. The crude mixture was purified by flash 
chromatography on SiO2 (2% MeOH/CH2Cl2), giving Compound 2 (1.4509 g, 69%) 
as a yellow oil. 
 
1H NMR: δ 8.09-8.07 (m, 1H), 7.70-7.68 (m, 2H), 7.63-7.62 (m, 1H), 4.37 (s, 2H), 
3.67-3.65 (m, 5H), 3.61-3.54 (m, 10H), 3.37 (s, 2H). 13C NMR: δ 169.6, 131.7, 130.9, 
124.2, 71.9, 70.6, 70.6, 70.4, 59.1, 52.2, 49.6, 48.2. 
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Compound 3 
 
MeO
O
N
Ns
O 3
2
PhSH, K2CO3
Acetonitrile
50 oC, 1h
MeO
O H
N
O 3
3  
 
To a solution of Compound 2 (1.01 g, 2.4 mmol) in acetonitrile (15 ml), benzenethiol 
(PhSH, 0.74ml) and potassium carbonate (1.33g, 9.6mmol) were added and warmed 
up to 50oC. After stirring for 1 hour at 50oC, the reaction mixture was cooled down to 
room temperature. After K2CO3 was filtered, the mixture was concentrated under 
reduced pressure and purified by flash chromatography on SiO2 with ethyl acetate 
(100 ml) first and then with 10% MeOH/CH2Cl2, giving Compound 3 (0.39 g, 69%) 
as a yellow oil. 
 
1H NMR: δ 3.72 (s, 3H), 3.65-3.59 (m, 8H), 3.56-3.54 (m, 2H), 3.46 (s, 2H), 3.37 (s, 
3H), 2.82-2.80 (m, 2H), 2.21 (s, 1H). 13C NMR: δ 170.0, 74.8, 74.5, 74.3, 69.4, 68.0, 
68.0, 67.8, 56.5, 49.2, 48.2, 46.2. 
 
Compound 4 
 
MeO
O H
N
O 3
LiOH
H2O, 50 oC, overnight
LiO
O H
N
O 3
3 4  
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A water (5 ml) solution of Compound 3 (193 mg, 0.82 mmol) and LiOH (32.7 mg, 
0.78 mmol) was warmed to 50oC. The mixture was stirred over night at 50oC. After 
the mixture was cooled down to room temperature, the reaction mixture was 
concentrated under a reduced pressure giving the target Compound 4 (the 
N-substituted amino acid, 153 mg, 82.1%) as a colorless oil. 
 
1H NMR (D2O): δ 3.66-3.58 (m, 12H), 3.35 (s, 3H), 3.26 (s, 1H), 2.87-2.84 (m, 2H). 
13C NMR (D2O): δ 177.5, 162.6, 71.0, 69.6, 69.5, 69.4, 69.4, 69.1, 68.6, 61.5, 58.0, 
51.6, 51.3, 47.1, 46.9, 34.0, 28.4. 
 
3.1.3 Functionalization of CNTs 
 
Scheme 3.1 
 
 
SWNT (22.8 mg) and paraformaldeyde (76 mg) were suspended in 45 ml of DMF. 
The heterogeneous mixture was heated at 130oC, while a solution of Compound 4 
(76 mg) in 5 ml DMF was added in portions (4 X 0.5 ml every 24 hours) and the 
reaction was continued for 5 days as described [Georgakilas et al., 2002]. The reaction 
was stopped after 5 days and the organic phase was separated from the unreacted 
material by centrifugation (2000xg, 10 min, room temperature) and filtration followed 
 38
by washing by CH2Cl2 for several times. The combined organics were evaporated 
under a reduced pressure and the remaining oily brown residue was extracted with 
CH2Cl2/H2O. The organic phase was washed three times with water, dried over 
Na2SO4, and concentrated to dryness giving functionalized CNTs (91.7 mg) as a 
brown solid. 
 
3.1.4 Nuclear Magnetic Resonance (NMR) 
 
NMR refers to a method that exploits the quantum mechanical magnetic properties of 
an atom’s nucleus to study molecules. It is a principal and powerful technique that can 
provide detailed physical, chemical, electronic and structural information about 
molecules. Nuclei that contain odd numbers of protons or neutrons could be observed 
by NMR. The most commonly measured nuclei are hydrogen-1 and carbon-13. In 
chemical synthesis studies, NMR is very powerful and useful technique that has been 
widely applied [Muller et al., 1997; Bahr et al., 2001; Kordatos et al., 2001; Brough et 
al., 2006]. By studying the peaks of NMR spectra, the structure of many compounds 
can be determined [Gottlieb et al., 1997]. 
 
In this research, we used NMR (propertied by Saskatchewan Structural Sciences 
Centre, University of Saskatchewan) to confirm the structure of the compounds that 
were synthesized from each step in the whole process of functionalizing CNTs. 
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Unless stated otherwise, NMR spectra were recorded at room temperature in CDCl3 
(1H at 500MHz, and 13C at 125 MHz). 
 
3.1.5 Transmission Electron Microscopy (TEM) 
 
TEM is a microscopy technique that can reveal an image of an ultra thin specimen 
through a beam of electrons. It is a very useful instrument that is widely used in 
material science and biological study [Pantarotto et al., 2003a; Bahr et al., 2001; Yu et 
al., 2008; Witus et al., 2007]. In this research, we utilized TEM for imaging the 
structure of pristine SWNT and f-CNTs. The samples were sent to the Department of 
Materials Engineering at the University of British Columbia. Specimen was prepared 
and imaged under a Hitachi H-800 electron transmission microscope at 100 kV. 
 
3.2 Biological experiments of plasmid DNA delivery and gene expression in vitro 
 
3.2.1 General methods and materials 
 
Plasmid transfection, a process of introducing nucleic acids (DNA or RNA) into cells 
by non-viral methods, is the most common way of studying gene delivery in vitro. We 
have two objectives in this section: 1) to determine whether f-CNTs generated in this 
thesis can deliver plasmid DNA into cells; and 2) whether f-CNTs can enhance gene 
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expression when a plasmid is transfected by a conventional method in the presence of 
f-CNTs.  
 
All the reagents, chemicals, and equipments needed for the biological experiments for 
gene expression were supplied by Vaccine and Infectious Disease Organization 
(VIDO) at the University of Saskatchewan, specifically Dr. Q. Liu’s Laboratory. They 
will be described along with the following description of major individual 
experiments. 
 
The Huh-7 cells were kindly provided by from Dr. Joyce Wilson (VIDO). Plasmid 
pLL166 is a plasmid vector containing no transgene, which was used as a negative 
control. Plasmids pLL122, pLL790 and pLL311 encoding luciferase, green 
fluorescent protein (GFP), and HCV core protein, respectively, were obtained from Dr. 
Q. Liu’s laboratory. 
 
3.2.2 Cell culture 
 
Huh-7 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% 4-(2-hydroxyethyl) 
piperazine-1-erhanesulfonic (HEPES) buffer, and 0.1% gentamicin antibiotic at 37oC 
in the presence of 5% CO2. 
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3.2.3 Calcium phosphate precipitation method 
 
Calcium phosphate precipitation method is based on the principle that spontaneous 
precipitation occurs in supersaturated solutions. When calcium chloride is added to 
the solution that contains phosphate at a low concentration, a fine precipitate of the 
positively charged calcium and the negatively charged phosphate will form, then 
when plasmid DNA is added to the suspension, it readily co-precipitates with the 
calcium phosphate and becomes adsorbed onto the cells [Graham et al., 1973; Jordan 
et al., 2004]. 
 
Plasmid DNA (1.0 μg) was dissolved in deionized water (45 μl). CaCl2 (5 μl) was 
then added to the plasmid DNA solution. Thereafter, 2 × 
N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) buffered solution (BBS, 
50 μl) was added to the mixture dropwise with vortexing. The mixture was allowed to 
incubate for 30 min at room temperature prior to use. 
 
3.2.4 Preparation of f-CNTs:DNA complexes 
 
Functionalized CNTs were diluted in an appropriate volume of deionized water at a 
concentration of 1.0 μg/μl and stored at 4oC until use. Plasmid DNA was hydrated in 
deionized water at a concentration of 1.0 μg/μl and stored frozen at -20oC until use. 
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3.2.4.1 Complexes for transfection using f-CNTs only 
 
Plasmid DNA (1.0 μg) was diluted in serum-free DMEM (300 μl). The f-CNTs (15 μg) 
were also diluted in DMEM (300 μl). Diluted plasmid and f-CNTs were mixed 
together by rapid pipetting for several times. Complexes were allowed to form for 30 
min at room temperature prior to use [Singh et al., 2005]. 
 
3.2.4.2 Complexes for transfection using f-CNTs and calcium phosphate 
 
Plasmid DNA (1 μg) was diluted in deionized water (22.5 μl). The f-CNTs (15 μg) 
were also diluted in deionized water (22.5 μl). Diluted plasmid and f-CNTs were 
mixed together by rapid pipetting for several times. CaCl2 (5 μl) was added to 
complexes after they were incubated for 30 min at room temperature and 2 × BBS (50 
μl) was added to the mixture dropwise with vortexing. The mixture was allowed to 
incubate for another 30min at room temperature prior to use. 
 
3.2.5 Transfections 
 
Transfection is the process of introducing genetic materials (such as plasmid DNA) 
into cells by non-viral methods 
[http://www.promega.com/guides/transfxn_guide/transfxn.pdf]. In this research, 
Huh-7 cells, a human hepatoma cell line, were cultured in DMEM supplemented with 
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10% FBS, 1% HEPES buffer, and 0.1% gentamicin antibiotic at 37oC in the presence 
of 5% CO2 and incubated overnight. When they reached 80% confluence, the Huh-7 
cells were transfected with (1) 1.0 μg plasmid DNA (negative control), (2) 1.0 μg 
plasmid DNA using calcium phosphate precipitation method, (3) f-CNTs:DNA 
complexes, (4) f-CNTs:DNA complexes with calcium phosphate precipitation method. 
Cells were incubated for 48 hours at 37oC with 5% CO2 in incubator. Two hours after 
the transfection, the serum-free DMEM used in preparation of f-CNTs:DNA 
complexes was replaced with DMEM supplemented with 10%FBS, 1% HEPES 
buffer, and 0.1% gentamicin antibiotic. 
 
3.2.6 Determining transfection efficiency using green fluorescent protein (GFP) 
 
GFP, isolated from the sea pansy (Renilla reniformis), has a single major excitation 
peak at 498 nm which is in the lower green portion of the visible spectrum and can be 
detected by a particular instrument such as a fluorescence microscope. The GFP gene 
has become a commonly used marker for studies of gene expression in many fields, 
including cell and molecular biology [Parsons et al., 2006; Philips, 2001; Chu et al., 
1999; Gao et al., 2006; Zhang et al., 2004]. 
 
3.2.6.1 Fluorescence analysis 
 
4',6-diamidino-2-phenylindole (DAPI) is a blue-fluorescent DNA stain that can be 
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used to stain the chromosome DNA in both live and fixed cells [Ma et al., 1996; 
Britton et al., 1998; Bailey et al., 2004]. It can easily enter cells, binds strongly to 
double-stranded DNA and emits blue emission. Its absorption maximum is at 358nm 
and its emission maximum is at 461nm 
[http://omlc.ogi.edu/spectra/PhotochemCAD/html/dapi(H2O).html]. By using spectral 
unmixing or taking images sequentially, DAPI blue emission is convenient for 
studying a single sample with the presence of GFP. By calculating GFP fluorescence 
(green) and DAPI fluorescence (blue) in the same field, the number of transfected 
cells and the total number of cells could be determined. The transfection efficiency 
could be evaluated by calculating the percentage of the cells with green fluorescence 
to total cells. 
 
Huh-7 cells were cultured in DMEM supplemented with 10% FBS, 1% HEPES buffer, 
and 0.1% gentamicin antibiotic in 2 well chamber slides (VWR) at 37oC in the 
presence of 5% CO2 and incubated overnight. When they reached 80% confluence, 
the Huh-7 cells were transfected with plasmid DNA pLL790 encoding GFP. 
Forty-eight hours after transfection, the culture medium was removed. Cells were 
washed with PBS buffer and were fixed by 4% paraformaldehyde (Sigma-Aldrich) for 
20 min. The paraformaldehyde was removed and the nuclei were stained by 300 nM 
DAPI for 5 min. Prolong Gold Antifade Reagent (Molecular Probes/Invitrogen) was 
used to mount the coverslips for viewing. The cells were observed and pictured using 
a Zeiss fluorescence microscope. The transfections were performed in duplicates. Five 
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fields of each sample were randomly chosen to be observed. Images were taken of 
both GFP fluorescence and DAPI fluorescence for counting GFP-expressing cells.  
 
The limitation of this technique is that some cells may be expressing very low levels 
of GFP even though they are transfected. In addition, the GFP has to fold properly to 
emit a strong fluorescence. Therefore, weak fluorescence may not be readily visible. 
 
3.2.6.2 Western blot analysis 
 
Western blotting is an analytical technique used to detect specific proteins in a given 
sample of tissue homogenate or extract [Burnette, 1981]. The sample can be separated 
by isoelectric charge, molecular weight, electric charge, or a combination of these 
factors, using gel electrophoresis. The proteins are then transferred to a membrane, 
where they are detected using antibodies specific to the target protein. This method is 
used in the fields of molecular biology, biochemistry, immunogenetics and other 
molecular biology disciplines [Zhu et al., 2004; Li et al., 2006; Tokushige et al., 1996; 
Jackel-Cram et al., 2007]. Western blot analysis usually can demonstrate the level of a 
protein present in a sample. 
 
Huh-7 cells were cultured in DMEM supplemented with 10% FBS, 1% HEPES buffer, 
and 0.1% gentamicin antibiotic in a 6-well plate at 37oC in the presence of 5% CO2 
and incubated overnight. When they reached 80% confluence, the Huh-7 cells were 
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transfected with plasmid DNA pLL790 encoding GFP. Cells were lysed in a lysis 
buffer (1% SDS, 10mmol/L Tris-HCl, pH 8.0) 48 hours after transfection. The protein 
concentration of lysed cells was determined by the Bradford assay (Bio-Rad) 
[http://www.technomedica.com/publikazii/belur/Bio-Rad.pdf] and read at 595 nm on 
an ELISA reader (SPECTRA max 340PC, Molecular Devices Corporation, Sunnyvale, 
CA, USA). Proteins separated in 12% polyacrylamide gels (at 120V for 45 min.) were 
transferred onto PVDF membranes (GE Healthcare) at 25V for 1.5 hours. The blots 
were blocked using PBS containing 2% non-fat milk for 2-4 hours. Membranes were 
then incubated at 4oC overnight with a GFP-specific monoclonal antibody (Q-Biogene) 
or β-actin-specific polyclonal antibody (Cell Signaling Technology). After washing 
with PBST (PBS with 0.05% Tween 20), membranes were then incubated with IR 
Dye 800-conjugated goat anti-mouse or IR Dye 680-conjugated goat anti-rabbit IgG 
antibody (Ly-Cor Biosciences) for 2 hours. After washing with PBS, the membranes 
were dried overnight in the dark. The protein bands on the membranes were 
visualized by the Li-Cor Odyssey scanner and subjected to densitometry analysis 
using the Quantity-One software (Bio-Rad). 
 
3.2.7 Determining gene expression using Luciferase 
 
Luciferase is a generic name for enzymes commonly used for bioluminescence. In a 
luciferase reaction, light is emitted when luciferase acts on the appropriate luciferin 
substrate. Photon emission can be detected by light sensitive apparatus such as a 
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luminometer [Promega Corporation. http://www.promega.com/multimedia/bioLum01.htm]. 
In biological research, luciferase commonly is used as a reporter to assess the level of 
gene expression in cells that are transfected with a genetic construct containing the 
luciferase gene [Jackel-Cram et al., 2007; Oem et al., 2007]. 
 
Huh-7 cells were cultured in DMEM supplemented with 10% FBS, 1% HEPES buffer, 
and 0.1% gentamicin antibiotic in a 24-well plate at 37oC in the presence of 5% CO2 
and incubated overnight. When they reached 80% confluence, the Huh-7 cells were 
transfected with plasmid DNA pLL122 encoding luciferase. Forty-eight hours after 
transfection, the culture medium was removed; the cells were washed with PBS buffer 
and lysed with 100μl/well Passive Lysis Buffer (Promega, 
http://www.promega.com/tbs/tm040/tm040.html) for 30 min. Twenty μl of cell lysate 
was added to 100 μl of Luciferase Assay Reagent (Promega, 
http://www.promega.com/tbs/tm040/tm040.html), mixed and read by a TD 20/20 
Luminometer (Turner Designs) for 10 seconds. The protein concentration of lysed 
cells was determined by the Bradford assay (Bio-Rad) and read at 595nm on an 
ELISA reader (SPECTRA max 340PC, Molecular Devices Corporation, Sunnyvale, 
CA, USA). 
 
3.2.8 Determining the expression of HCV core protein after transfection 
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Huh-7 cells were cultured in DMEM supplemented with 10% FBS, 1% HEPES buffer, 
and 0.1% gentamicin antibiotic in a 6-well plate at 37oC in the presence of 5% CO2 
and incubated overnight. When they reached 80% confluence, the Huh-7 cells were 
transfected with plasmid DNA pLL311 encoding HCV core protein. Cells were lysed 
in a lysis buffer (1% SDS, 10mmol/L Tris-HCl, pH 8.0) 48 hours after transfection 
and examined by Western blot analysis using a core-specific antibody. 
 
3.2.9 Agarose gel electrophoresis assay 
 
Agarose gel electrophoresis is a method used in biochemistry and molecular biology 
to separate DNA (or RNA) molecules by size. This is achieved by forcing negatively 
charged DNA to migrate to the positive pole in an electric field through a sieve of 
molecular proportions that is made of agarose. After electrophoresis, the gel which is 
stained with ethidium bromide, is illuminated with an ultraviolet lamp in a light box 
to view the DNA bands. The gel can then be photographed with a digital or polaroid 
camera. 
 
In this study, we utilized this assay to analyze the interaction between plasmid DNA 
and f-CNTs, in particular we examined whether f-CNTs bind with plasmid DNA. Our 
approach was as this. When plasmid DNA and f-CNTs are mixed, if f-CNTs bind 
with plasmid DNA and form a stable complex, they will be in the sediment of the 
mixture, and this also mean that the supernatant will not have free plasmid DNAs. 
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When a sufficient amount of free plasmid DNAs move into the gel, a DNA band can 
be observed with the ethidium bromide staining. This helps judge whether there is 
plasmid DNA in a mixture (supernatant or sediment). 
 
Plasmid DNA (pLL122, 1μg) was incubated with f-CNTs (15μg) for 30min at room 
temperature. The mixtures were then centrifuged at 6000g for 10min. The 
supernatants that contain free plasmid DNAs with several different amounts (1μl, 5μl, 
and 10μl, respectively) were loaded on an agarose gel with 1μg/ml Ethidium Bromide. 
Furthermore, sediment (5μl and 25μl) was also loaded on the gel with 1μg/ml 
Ethidium Bromide. Electrophoresis was carried out with a current of 120V for 20min. 
 
3.2.10 Statistical analysis 
 
All the transfections were performed in triplicates and the experiments were repeated 
at least two times. Results were analyzed for statistical differences using Student’s t 
test. A p value of ≤0.05 was considered to be statistically significant.
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Chapter 4  
Results and Discussion 
 
4.1 Results 
 
4.1.1 Characterization of functionalized CNTs 
 
The CNTs were functionalized with the synthesized amino acid via 1,3-dipolar 
cycloaddition reaction as described in Chapter 3. The products from each step were 
characterized by nuclear magnetic resonance (NMR) analysis. 
 
Before the CNTs were functionalized, the N-substituted amino acid was first 
synthesized with a method as described by Brough et al. However, this attempt was 
successful; see also discussion in Section 3.1.2.1. Therefore, a modified procedure 
was proposed to make the target compound (Compound 4). Unlike the procedure of 
Brough’s method, a pure and well-characterized Compound 4 was prepared 
successfully and used for the following functionalization of CNTs (Scheme 4.1).  
 
 
 
Scheme 4.1 
 
 
 
After 1,3-dipolar cycloaddition reaction, product f-CNTs were first analyzed by NMR. 
NMR demonstrated the presence of the pyrrolidines rings and the poly ethylene glycol 
chains. The NMR spectra can be found in the appendix of this thesis. 
 
As well, the pristine CNTs and f-CNTs were both examined by transmission electron 
microscopy (TEM); see Figure 4.1. In particular, Fig. 4.1 C and D show the TEM 
image of pristine CNTs, which appear to have coarser surfacs. It is noted that the 
TEM image of Fig. 4.1 C and D are much similar with those in the SWNT 
specification provide by Carbon Nanotechnologies Inc. Fig. 4.1 A and B show the 
TEM image of f-CNT; especially Fig. 4.1 B is an amplification of the area denoted by 
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“B” in Fig. 4.1 A. The substance on the upper left corner in Fig. 4.1 A was likely 
chemical impurities. It should be noted that the CNT shown in Fig 4.1 A and B is bulk 
CNT due to the limitation of resolution of the TEM used and insufficient dispersion of 
CNT in the sample preparation for TEM imaging. Nevertheless, the TEM images of 
Fig.4.1 A and B appear to indicate the f-CNT has a relatively smooth surface covered 
by chemical coatings, which was expected from the functionalization process. 
 
 
Figure 4.1 TEM image of f-CNT (A, B, C, D) and pristine CNTs (E, F). 
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 Figure 4.2 Pristine CNTs in water (left); f-CNTs in water (right). 
 
Figure 4.2 shows two bottles with one containing water and pristine CNTs (left) and 
the other containing water and the f-CNTs that was prepared from N-substituted 
amino acid; see discussion in section 3.1.2. From this figure, it is clear that the 
pristine CNTs were not soluble in water, as there are many CNTs suspending in water. 
The f-CNTs, however, are soluble, as there is nearly no black CNT in water.  
 
In short, the three examinations (NMR, TEM, and solubility test in water) indicated 
that the expected structure of f-CNTs as shown in Scheme 4.1 (see pervious 
discussion in section 4.1.1) has been obtained. 
 
4.1.2 Determining transfection efficiency and gene expression using green 
fluorescent protein (GFP) as a reporter 
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To investigate the transfection efficiency of the f-CNTs delivery system, Huh-7 cells 
were transfected by plasmid DNA pLL790 encoding GFP as described in Chapter 3. 
Forty-eight hours after transfection, cells were analyzed by fluorescence analysis (Fig. 
4.3) and Western blot analysis. 
 
Fluorescent analysis demonstrated that incubating the cells with plasmid DNA alone 
did not give detectable fluorescence as expected (Fig. 4.3 B). A complex containing 
f-CNTs and plasmid DNA also did not result in any fluorescence (Fig. 4.3 C and D). 
In contrast, green fluorescence was detected after transfection with calcium phosphate 
with or without f-CNTs. The transfection efficiency using calcium phosphate (CaP) 
alone was 23.7% (Fig. 4.3 E and F, Fig. 4.4), which the transfection efficiency using 
CaP and f-CNT was 27.9% (Fig. 4.3 G and H, Fig. 4.4). However, there was no 
statistical difference in transfection efficiency between calcium phosphate 
precipitation method and its combination with f-CNTs (p=0.18). Interestingly, the 
f-CNTs alone did not confer any detectable transgene expression in contrast. 
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 Figure 4.3 DAPI (blue) and GFP (green) fluorescent images of Huh-7 cells 
transfected with a plasmid encoding GFP via various delivery systems. 
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Figure 4.4 Evaluation of the transfection efficiency of a plasmid encoding GFP 
(pLL790) by using various delivery systems. 
 
Consistent with the results of fluorescent microscopy, Western blot analysis showed 
that there was no GFP expression in the cells which have been exposed to f-CNTs 
complexed with plasmid DNA (Fig. 4.5a). The cells transfected by either calcium 
phosphate method or its combination with f-CNTs were all expressing GFP. When the 
levels of GFP were normalized against those of a housekeeping gene β-actin, f-CNTs 
were shown to enhance GFP expression when it was combined with calcium 
phosphate (see Fig. 4.5b, p=0.38). However, such an enhancement was not 
statistically significant. 
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 Figure 4.5 GFP western blotting of Huh-7 transfected via various delivery systems. 
 
4.1.3 Determining gene expression using luciferase as a reporter 
 
Plasmid pLL122 encoding luciferase was transfected to Huh-7 cells as described in 
Chapter 3. Luciferase assay was carried out 48 hours after transfection. Luciferase 
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activity of cells that is transfected via calcium phosphate precipitation method and the 
combined method of f-CNTs and calcium phosphate resulted in significantly higher 
luciferase activity than plasmid only transfection (Fig. 4.6). 
 
 
Figure 4.6 Normalized luciferase activity of Huh-7 cells transfected with a plasmid 
enconding luciferase gene (pLL122) via various delivery systems 
 
Importantly, cells transfected via the combined method exhibited significantly higher 
luciferase activity than calcium phosphate method only (Fig.4.6, CaP method vs. 
f-CNTs and CaP combined method, p=0.027). After transfection via f-CNT delivery 
system, luciferase activity was barely detectable. There was only a minor difference in 
luciferase activity between control (plasmid only) transfection and f-CNTs 
transfection (Fig. 4.7). The result of luciferase assay indicated that f-CNTs played a 
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role of enhancing luciferase gene expression of calcium phosphate method in Huh-7 
cells. 
 
 
Figure 4.7 Normalized luciferase activity of Huh-7 cells transfected by plasmid 
pLL122 or via f-CNTs delivery system. 
 
4.1.4 Determining the level of HCV core protein expression 
 
Huh-7 cells were transfected by plasmid DNA pLL311 encoding HCV core protein as 
described in Chapter 3. The level of HCV core was examined by Western blot 
analysis 48 hours after transfection. 
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Western blot analysis demonstrated that there was no expression of HCV core protein 
in cells with plasmid DNA complexed with f-CNT (Fig. 4.8a). The cells were 
transfected by calcium phosphate method and its combination with f-CNTs delivery 
system were all expressing HCV core protein. The cells transfected by the combined 
method exhibited much higher core protein expression than the ones transfected by 
calcium phosphate method when they were normalized against β-actin levels; 
however statistically such a difference is not significant – see Fig. 4.8b (p=0.41). 
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 Figure 4.8 HCV core protein expression analyzed by Western blotting of Huh-7 cells 
transfected with a plasmid encoding HCV core protein (pLL311) via various delivery 
systems. 
 
 62
4.1.5 Agarose gel electrophoresis assay for plasmid DNA binding with f-CNTs 
 
To investigate the interaction between plasmid DNA and f-CNTs, agarose gel 
electrophoresis assay was carried out as described in Chapter 3. As shown in Fig. 4.9, 
the DNA bands of free DNAs in the supernate of the mixture of plasmid DNA and 
f-CNT can be observed; but no DNA band can be observed of the sediment of the 
mixture. 
 
 
Figure 4.9 The interaction between plasmid DNA and f-CNTs analyzed by agarose 
gel electrophoresis. (1) 1μl surpernate, (2) 5μl supernate, (3) 10μl supernate, (4) 5μl 
sediment, and (5) 25μl sediment 
 
The above result suggests that f-CNTs did not bond with plasmid DNA (pLL122) 
effectively; otherwise there should be plasmid DNAs in the sediments of the mixture 
of f-CNTs and plasmid DNAs water solution. 
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4.2 Discussion 
 
We initially encountered problems in synthesizing N-substituted amino acid by 
following Brough’s method [2006]. Therefore, a glycine methyl ester hydrochloride 
was chosen as the starting material, which was readily prepared from a commercially 
available glycine. Further, Brough’s method, the N-substituted amino acid 
(Compound C, section 3.1.2.1) was not purified from the reaction mixture and used 
directly for their subsequent reactions. The impurities would bring the complexity to 
the following step because in our case, it was difficult to isolate f-CNTs with 
appreciable purity.  
 
We further modified Brough’slast step based on Sakaguchi’s method [2007] with 
some changes (see later discussions). The change was that we divided Brough’s last 
step (see section 3.1.2.1, Compound B to Compound C) into two individual steps 
(see section 3.1.2.2, Compound 2 to Compound 3, Compound 3 to Compound 4). 
In Brough’s procedure, solvent DMF and excess LiOH (2 equivalent of Compound B) 
were used without isolation of intermediate compound; the disadvantage with that 
was that it was not easy to remove residual DMF and unreacted LiOH from lithium 
salt of Compound C. The NMR spectrum of their final Compound C did not seem 
to be consistent with the structure they proposed and the purification procedure in 
their supplementary information was not complete. Therefore, we chose to prepare 
pure intermediate Compound 3 by removing the protecting group from Compound 2 
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first. With pure Compound 3 in hand, we used less LiOH (0.9 equivalent of 
Compound 3). Thus in the resulting reaction mixture, there was no LiOH and the 
only impurity was the unreacted Compound 3 which was removed readily by 
extraction. After evaporation of the aqueous layer from extraction, Compound 4 was 
obtained as a pure compound. 
 
The main purpose of functionalization in this research was to introduce particular 
functional groups onto CNT sidewalls so that it could be dissolved in water. The 
successful synthesis of N-substituted amino acid (Compound 4) was critical for this 
functionalization because our N-substituted amino acid contained poly (ethylene 
glycol) (PEG) chain which was the source of the particular functional group. The PEG 
chain which is highly hydrophilic and therefore can increase the hydrophilicity of 
CNTs, and the pyrrolidine ring can form ammonium salt to enhance their solubility in 
water. The solubility of CNTs in water opens the gate for its biological and 
biomedical applications. It allows us to explore its function as a drug/gene delivery 
system which could apply to biological, immunological, and pharmacological studies. 
 
Several research groups demonstrated that CNTs, including single-wall CNTs and 
multi-wall CNTs, can be functionalized and utilized in gene delivery applications 
[Bianco et al., 2005a; Rojas-Chapana et al. 2005; Singh et al., 2005, Pantarotto et al., 
2004; Gao et al., 2006; Pan et al., 2007]. In this study, a series of biological 
experiments was carried out to investigate the ability and efficiency of our f-CNTs as 
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a gene delivery system. Human hepatoma cells were transfected with three plasmid 
DNAs encoding three different genes, respectively, which was delivered by: (1) 
f-CNTs, (2) calcium phosphate precipitation method, and (3) a combination of 
f-CNTs and calcium phosphate method. Different assays and analyses were carried 
out to determine the levels of protein expression. 
 
Negatively charged plasmid DNA could well bind to the functionalized CNTs which 
have positively charged groups (such as ammonium group) on their surface [Pan et al., 
2007; Singh et al., 2005; Pantartto et al., 2004; Gao et al., 2006]. In this study, the 
functional group PEG chains on f-CNTs surface was neutral, which explained the lack 
of success of interaction between f-CNTs and plasmid DNA. The biological 
experimental results in this thesis showed that the level of gene expression conferred 
by plasmid DNA complexed with our f-CNTs had only a minor difference with the 
negative control (i.e., when the cells were incubated with plasmid DNA only) in 
Huh-7 cells. 
 
Interestingly, when we combined the f-CNTs with a conventional transfection method 
(i.e., calcium phosphate precipitation method), the gene expression levels were 
enhanced. It is noted that although only one measurement showed that this 
enhancement was statistically significant; all the measurements did show the trend of 
this enhancement. In fact, these measurements, e.g. western blot analysis, was done 
only three times, which we believed is not sufficient to perform t-test. We expected 
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that more replicates of these measurements would show this enhancement statistically 
significant.  
 
Nevertheless, sufficient evidences have shown that our f-CNT enhance the calcium 
phosphate method in gene expression. This result may be explained by the following 
conjecture. The calcium phosphate transfection method relies on the coprecipitation 
of plasmid DNAs formed with calcium phosphate. The complex (coprecipitated 
compound) may further be presented to the cell surface, and the plasmid DNA is 
taken by the cell via endocytosis [Jordan et al., 2004]. The PEG side chains on 
f-CNTs or f-CNTs themselves may cross-link to form a network structure 
[Correa-Duarte et al., 2004; Xie et al., 2004] via electrostatic interaction probably. 
This network may enhance the complex of calcium phosphate and plasmid DNAs in 
transportation to cells. However, the actual interaction among f-CNTs, plasmid DNA, 
and calcium phosphate need to be fully investigated. 
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Chapter 5  
Conclusion and Future Work 
 
5.1 Conclusions 
 
This study was motivated by an observation that the delivery of plasmid DNA for 
HCV vaccine in large animals is not effective, and nanotechnology may be a 
promising approach to improve this situation. The research was aimed to develop a 
nano delivery system for plasmid DNA to human hepatoma cells (Huh-7 cells). In 
particular, two major experiments were conducted in this study: functionalization of 
carbon nanotubes and comparative biological experiments of the f-CNTs delivery 
system and conventional delivery method in vitro. 
 
The study concludes: 
 
(1) The single-wall carbon nanotubes can be functionalized to form a large 
number of PEG side chains stably through a proposed method which revises 
Brough’s method so that the functionalized single-wall carbon nanotubes are 
water soluble. 
(2) The functionalized CNTs significantly enhanced gene expression when 
combined with calcium phosphate for plasmid DNA transfection. 
(3) The functionalized CNTs complexed with plasmid DNA did not result in 
detectable gene expression in human hepatoma Huh-7 cells. This is likely 
because the f-CNTs (in particular N-substituted amino acid) do not bind with 
plasmid DNAs in water solution. 
 
5.2 Limitation and Future Work 
 
Gene expression in Huh-7 cells after transfection with a plasmid DNA complexed 
with f-CNTs alone was at an undetectable level. However, it was found that f-CNTs 
can enhance the level of gene expression of calcium phosphate precipitation method 
in delivering plasmid DNA into Huh-7 cells. The mechanism of how this new 
approach works is to be unfolded. Furthermore, this study has only investigated 
single-wall CNTs and one functional group to CNTs (i.e., PEG side chain). With an 
overview of the contemporary literature on f-CNTs-based nano drug delivery systems 
(see Chapter 2 of this thesis) and the limitation of the knowledge generated from this 
thesis work, a couple of thoughts for future work on the drug/gene delivery system for 
the HCV vaccination development are discussed in the following. 
 
First, it should be interesting to study the effect of multi-walled carbon nanotubes for 
plasmid DNA delivery systems. There have been ample evidences to show different 
properties in many aspects (e.g., absorption of H2S in sera [Zhan, 2008]) between 
single-wall CNTs and multi-wall CNTs. 
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 Second, it is warranted that different functional groups to CNTs with different 
functionalization processes should be examined. Different functional groups may 
have different binding capabilities with plasmid DNA and possibly different binding 
affinities with Huh-7 cells. These interactions are primarily responsible for different 
drug delivery performances. 
 
Third, there is a need to study the mechanism of integration of f-CNTs and calcium 
phosphate given the finding that their combination can significantly improve the gene 
expression. The goal of this study is to optimize the design of such a combined system 
for the best delivery performance. This goal seems to be achievable. Our preliminary 
experiments have shown that the amount of f-CNTs may play a role in the delivery 
performance and an optimal amount of f-CNTs makes sense. 
 
Finally, in all the studies including both the present and future work, there is a need to 
study the selectivity of the delivery. To make the delivery system work for large 
animals and humans in vivo, not only the delivery efficiency is important but also the 
drug selectivity (or in engineering terminology, the robustness of a process) should be 
a concern. 
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